Early safety check for COVID antibody cocktail
NCT ID NCT05181683
Summary
This early-stage study tested the safety of a combination of two lab-made antibodies (casirivimab+imdevimab) against COVID-19. It involved 45 healthy or medically stable adult volunteers who received the antibodies either as an injection under the skin or through an IV drip. The main goal was to check for side effects and see how the body processes these antibodies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Study Site
Miami, Florida, 33186, United States
-
Regeneron StudySite
Winter Park, Florida, 32789, United States
Conditions
Explore the condition pages connected to this study.